arrow
A

Agnese Fabbri

Central Hospital of Belcolle
H指数:23
被引数:1,739

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial

基因组匹配疗法在晚期实体瘤中的应用:随机II期ROME试验

2025-09-290
OAAI
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

ramucirumab联合卡铂和紫杉醇治疗未治疗的转移性胸腺癌的疗效和安全性: RELEVENT II期试验 (NCT03921671)

2024-09-012
OA
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (vol 10, 58, 2024)

药物-药物相互作用对abemaciclib在AB-意大利研究的真实世界经验中的临床影响 (第10卷,58卷,2024)

2024-08-020
OAAI
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

在AB-意大利研究的现实世界经验中,药物-药物相互作用对abemaciclib的临床影响

2024-07-173
OAAI
Herpes zoster after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: a prospective study
2024-01-200
OAAI
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study

接受靶向治疗的晚期乳腺癌患者接受第三剂SARS-CoV-2 mRNA-BNT162b2疫苗后的免疫反应和临床结局: 一项前瞻性研究

2023-11-071
OAAI
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study

DARPP-32和t-darpp在anti-HER2药物抗性发展中的作用。STEP研究的临床前证据

2023-11-011
OAAI
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

HER2-positive乳腺癌患者新辅助化疗加或不加帕妥珠单抗后的病理反应和生存率: Neopearl全国合作研究

2023-06-271
OAAI
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

卡培他滨辅助治疗新辅助治疗后有残留病灶的三阴性乳腺癌患者: 来自CaRe的真实世界证据,一项多中心观察性研究

2023-05-165
OAAI
DE-REAL: ITALIAN MULTICENTER EXPERIENCE OF TRASTUZUMAB DERUXTECAN IN A REAL WORLD SETTING
2023-03-010
PRE
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients

癌症患者第三剂SARS-CoV-2 mRNA-BNT162b2疫苗后外周血淋巴细胞和抗体反应的动态变化

2022-12-195
OAAI
Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
2022-07-016
OAAI
Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study

外周血淋巴细胞亚群计数可预测癌症患者SARS-CoV-2 mRNA-BNT162b2疫苗后的抗体反应: vax-on-Profile研究的结果

2022-07-017
OAAI
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

CDK4/6抑制剂Ribociclib在局部晚期和寡转移性激素受体阳性,Her2阴性,晚期乳腺癌中的作用: 病例系列和文献复习

2022-02-092
OAAI